Clementia Pharmaceuticals

Clementia Pharmaceuticals is a clinical-stage company dedicated to providing innovative treatments for patients with ultra-rare bone disorders. The company develops disease-modifying therapies for patients suffering from debilitating bone conditions and other unmet medical needs. Its lead product candidate, palovarotene, is an oral small molecule that has demonstrated effective activity in preventing abnormal new bone formation and fibrosis across various tissues.